Tilray Brands, Inc. (2HQ.DE)
EUR 0.42
(0.58%)
EUR 0.42
(0.58%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 778.48 Million USD | -20.34% |
| 2022 | 977.31 Million USD | -3.08% |
| 2021 | 1 Billion USD | -35.37% |
| 2020 | 1.56 Billion USD | 227.82% |
| 2019 | 475.89 Million CAD | -9.11% |
| 2018 | 523.6 Million CAD | 380.55% |
| 2017 | 108.95 Million CAD | 248.65% |
| 2016 | 31.25 Million CAD | 3118.36% |
| 2015 | 971.04 Thousand CAD | 27.4% |
| 2014 | 762.17 Thousand CAD | 2663.6% |
| 2013 | 27.57 Thousand CAD | 164.32% |
| 2012 | 10.43 Thousand CAD | -5.8% |
| 2011 | 11.07 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 778.45 Million USD | 2.39% |
| 2023 Q3 | 869.81 Million USD | -7.19% |
| 2023 Q4 | 778.48 Million USD | -10.5% |
| 2023 FY | 778.48 Million USD | -20.34% |
| 2023 Q1 | 1 Billion USD | 2.39% |
| 2023 Q2 | 937.2 Million USD | -6.34% |
| 2022 Q3 | 969.12 Million USD | -2.23% |
| 2022 Q1 | 1.02 Billion USD | 2.08% |
| 2022 FY | 977.31 Million USD | -3.08% |
| 2022 Q4 | 977.31 Million USD | 0.84% |
| 2022 Q2 | 991.23 Million USD | -3.7% |
| 2021 Q3 | 1.15 Billion USD | -10.23% |
| 2021 Q1 | 1.6 Billion USD | 2.6% |
| 2021 FY | 1 Billion USD | -35.37% |
| 2021 Q4 | 1 Billion USD | -12.96% |
| 2021 Q2 | 1.29 Billion USD | -19.37% |
| 2020 FY | 1.56 Billion USD | 227.82% |
| 2020 Q2 | 665.27 Million USD | 35.91% |
| 2020 Q3 | 972.32 Million CAD | 46.15% |
| 2020 Q4 | 1.56 Billion USD | 60.44% |
| 2020 Q1 | 489.49 Million USD | 2.86% |
| 2019 FY | 475.89 Million CAD | -9.11% |
| 2019 Q3 | 550.84 Million USD | -0.23% |
| 2019 Q2 | 552.12 Million USD | 8.8% |
| 2019 Q4 | 475.89 Million USD | -13.61% |
| 2019 Q1 | 507.47 Million USD | -3.08% |
| 2018 Q1 | 127.25 Million USD | 16.79% |
| 2018 Q2 | 228.02 Million USD | 79.19% |
| 2018 Q4 | 523.6 Million USD | 102.34% |
| 2018 Q3 | 258.78 Million USD | 13.49% |
| 2018 FY | 523.6 Million CAD | 380.55% |
| 2017 Q3 | 85.1 Million USD | 112.78% |
| 2017 Q2 | 39.99 Million USD | 24.31% |
| 2017 Q1 | 32.17 Million CAD | 2.96% |
| 2017 FY | 108.95 Million CAD | 248.65% |
| 2017 Q4 | 108.95 Million USD | 28.03% |
| 2016 Q4 | 31.25 Million CAD | 207.59% |
| 2016 Q2 | 7.97 Million CAD | 0.26% |
| 2016 Q1 | 7.94 Million CAD | 718.69% |
| 2016 FY | 31.25 Million CAD | 3118.36% |
| 2016 Q3 | 10.16 Million CAD | 27.47% |
| 2015 FY | 971.04 Thousand CAD | 27.4% |
| 2015 Q1 | 1.2 Million CAD | 57.8% |
| 2015 Q2 | 1.2 Million CAD | -0.06% |
| 2015 Q3 | 1.18 Million CAD | -1.09% |
| 2015 Q4 | 971.04 Thousand CAD | -18.33% |
| 2014 Q4 | 762.17 Thousand CAD | 23.73% |
| 2014 FY | 762.17 Thousand CAD | 2663.6% |
| 2014 Q3 | 615.99 Thousand CAD | 2214.8% |
| 2014 Q2 | 26.61 Thousand CAD | -3.51% |
| 2014 Q1 | 27.57 Thousand CAD | -72.39% |
| 2013 Q1 | 10.43 Thousand CAD | 258.47% |
| 2013 FY | 27.57 Thousand CAD | 164.32% |
| 2013 Q4 | 99.9 Thousand CAD | 145.6% |
| 2013 Q3 | 40.67 Thousand CAD | 434.8% |
| 2013 Q2 | 7605.87 CAD | -27.1% |
| 2012 FY | 10.43 Thousand CAD | -5.8% |
| 2012 Q1 | 11.07 Thousand CAD | -40.98% |
| 2012 Q2 | 30.77 Thousand CAD | 177.87% |
| 2012 Q3 | 15.19 Thousand CAD | -50.64% |
| 2012 Q4 | 2910.70 CAD | -80.84% |
| 2011 FY | 11.07 Thousand CAD | 0.0% |
| 2011 Q4 | 18.76 Thousand CAD | 175.84% |
| 2011 Q2 | 48.28 Thousand CAD | 0.0% |
| 2011 Q3 | 6803.25 CAD | -85.91% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| MPH Health Care AG | 15.38 Million EUR | -4959.55% |
| Apontis Pharma AG | 27.2 Million EUR | -2762.085% |
| Dermapharm Holding SE | 1.62 Billion EUR | 52.145% |
| Evotec SE | 1.17 Billion EUR | 33.979% |
| MERCK Kommanditgesellschaft auf Aktien | 22.36 Billion EUR | 96.519% |
| PharmaSGP Holding SE | 91.54 Million EUR | -750.387% |
| SynBiotic SE | 19.59 Million EUR | -3873.704% |